公开(公告)号：US20190290706A1

公开(公告)日：2019-09-26

申请号：US16308330

申请日：2017-06-08

Applicant: SOFAR S.P.A.

Inventor： Andrea BIFFI ,  Walter FIORE ,  Ruggero ROSSI

IPC: A61K35/747 ,  A61K36/064 ,  A61P1/00 ,  A61K9/00 ,  A61K35/745

Abstract: The present invention relates to the use of a composition based on bacteria and/or yeasts and/or other microorganisms, taken singularly or in combination, for the treatment of the symptoms of and/or for treating Irritable Bowel Syndrome (IBS) or also similar pathologies affecting the gastrointestinal apparatus. In particular, the bacteria are selected from the following genera: Lactobacillus, Bifidobacterium, Bacillus, Propionibacterium, Streptococcus, Lactococcus, Aerococcus and Enterococcus.

公开(公告)号：US20200061141A1

公开(公告)日：2020-02-27

申请号：US16465511

申请日：2017-12-01

Applicant: SOFAR S.P.A.

Inventor： Andrea BIFFI ,  Ruggero ROSSI ,  Walter FIORE ,  Silvia SALAMINA

IPC: A61K36/45 ,  A61K31/353 ,  A61K9/28

Abstract: The present invention relates to a composition which comprises a mixture which comprises or, alternatively, consists of an extract (a) of a fruit of at least one plant of the genus Vaccinium and at least one ingredient (b) acceptable for pharmaceutical or food use and the use thereof in the prevention and/or treatment of diverticular disease or of a pathology deriving therefrom or correlated thereto.

公开(公告)号：US20160296569A1

公开(公告)日：2016-10-13

申请号：US14916961

申请日：2014-09-05

Applicant: SOFAR S.P.A.

Inventor： Simone Domenico GUGLIELMETTI ,  Ruggero ROSSI ,  Walter FIORE ,  Andrea BIFFI

IPC: A61K35/747 ,  A61K9/48 ,  A61K9/00

CPC classification number: A61K35/747 ,  A23L33/135 ,  A23L33/21 ,  A23V2002/00 ,  A23Y2220/63 ,  A61K9/0053 ,  A61K9/48 ,  A61K2035/11 ,  A61P1/00 ,  A23V2200/32 ,  A23V2200/3202 ,  A23V2200/3204

Abstract: The present invention relates to the use of a composition comprising bacteria to increase the intestinal production of butyric acid, folic acid or niacin and/or to decrease the intestinal production of succinic acid. Moreover, the present invention relates to the use of said composition for the treatment and/or prevention of an intestinal butyrate- and/or succinate-dependent pathological condition. In particular, for the treatment and/or the prevention of intestinal inflammation, diarrhoea, ulcerative colitis or intestinal colopathies.

Abstract translation: 本发明涉及包含细菌的组合物增加丁酸，叶酸或烟酸的肠内产生和/或降低琥珀酸的肠内产生的用途。 此外，本发明涉及所述组合物用于治疗和/或预防肠内丁酸酯和/或琥珀酸依赖性病理状况的用途。 特别地，用于治疗和/或预防肠道炎症，腹泻，溃疡性结肠炎或肠道共病。

公开(公告)号：US20210236565A1

公开(公告)日：2021-08-05

申请号：US16467797

申请日：2017-12-15

Applicant: SOFAR S.P.A.

Inventor： Andrea BIFFI ,  Walter FIORE ,  Ruggero ROSSI

IPC: A61K35/747 ,  A23L33/135 ,  A61K35/745 ,  A61K36/06 ,  A61K9/00 ,  A61K9/48

Abstract: The present invention relates to the use of probiotics to control the inflammatory process of the colon in subjects with structural modifications of the colon wall, preferably in subjects with diverticulosis, and affected by diverticular disease.

公开(公告)号：US20160348155A1

公开(公告)日：2016-12-01

申请号：US14916959

申请日：2014-09-05

Applicant: SOFAR S.P.A.

Inventor： Simone Domenico GUGLIELMETTI ,  Ruggero ROSSI ,  Walter FIORE ,  Andrea BIFFI

IPC: C12Q1/68

CPC classification number: C12Q1/689 ,  A23L33/135 ,  A61K35/747 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/158

Abstract: The present invention relates to a method for determining the probiotic/paraprobiotic activity of a composition comprising microorganisms, in particular bacteria, said method being based on evaluating, by metagenomic analysis, the qualitative and/or quantitative change in faecal microbiota following intake of the composition. Moreover, the present invention relates to a kit for carrying out said method.

Abstract translation: 本发明涉及一种用于确定包含微生物，特别是细菌的组合物的益生菌/副生物活性的方法，所述方法基于通过宏基因组分析来评估吸入组合物后粪便微生物群的定性和/或定量变化 。 此外，本发明涉及一种用于执行所述方法的套件。